06:46 AM EST, 01/07/2025 (MT Newswires) -- AbbVie ( ABBV ) said in a regulatory filing late Monday that its Q4 earnings are expected to include acquired In-Process Research & Development and milestone expense of $1.57 billion on a pre-tax basis.

AbbVie ( ABBV ) said it now expects Q4 adjusted earnings of $2.06 to $2.10 per diluted share versus the previous estimate of $2.94 to $2.98. Analysts surveyed by FactSet expect $2.98.

Adjusted earnings for fiscal 2024 are now expected to be $10.02 to $10.06 per diluted share, compared with its previous forecast of $10.90 to $10.94. Analysts surveyed by FactSet expect $10.94.